Loading
A phase 2 trial of Tremelimumab in mesothelioma, run by MedImmune LLC, active and no longer recruiting.
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma is a phase 2 interventional study registered as NCT01843374 by MedImmune LLC, with 571 participants enrolled, started 2013-05-17 and due to reach its primary completion in 2016-01-24. Interventions recorded: Tremelimumab, Placebo. Conditions listed: Unresectable Pleural or Peritoneal Malignant Mesothelioma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Peritoneal mesothelioma, Pleural mesothelioma, Mesothelioma.
Shares Tremelimumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Tremelimumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Shares Pleural mesothelioma, Mesothelioma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/